European Medicines Agency (EMEA) recommends withdrawal of Benfluorex from the market in European Union
Last Updated on December 31, 2009 by Joseph Gut – thasso
December 31, 2009 – The European Medicines Agency (EMEA) has recommended the withdrawal of all medicines containing Benfluorex in the European Union, because their risks, particularly the risk of heart valve disease, are greater than their benefits.
Doctors should stop prescribing Benfluorex-containing medicines and consider alternative treatments. Patients currently taking the medicines should make an appointment with their doctor at a convenient time. Because heart valve disease can develop some years after treatment, patients who have taken Benfluorex in the past should tell their doctor so that they can be checked for the signs and symptoms of heart valve disease.
Benfluorex is approved for use in overweight patients with diabetes, combined with an appropriate diet.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) reviewed available data on the safety and efficacy of these medicines because the French and Portuguese authorities had recalled them from their markets over safety concerns. The Committee concluded that the data indicate a risk of heart valve diseases associated with the use of Benfluorex. The Committee also noted that the efficacy of Benfluorex in the treatment of diabetes is limited. The Committee therefore was of the opinion that the benefits of these medicines no longer outweigh their risks and recommended the revocation of their marketing authorisations from all markets in the European Union.
The Committee’s opinion has been forwarded to the European Commission for the adoption of a decision. This press release, together with other information on the work of the European Medicines Agency, can be found on the Agency’s website.
July 1...July 12, 2016
August...August 21, 2022
19...April 19, 2019
Apri...April 6, 2016
Octobe...October 16, 2022